SCHEMBL2854997

SCHEMBL2854997

Nc1cccc(S(=O)(=O)NCCN2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
PRMT1 Q99873 1/20 0.56
PARP1 P09874 3/20 0.54
TP53 P04637 1/20 0.53
MAPK1 P28482 1/20 0.53
CYP19A1 P11511 1/20 0.52
SRC P12931 1/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2850490 0.99 L3MBTL1 (0.58) SIGMAR1L3MBTL1PRMT1PARP1TP53
SCHEMBL17374111 0.88 PRMT1 (0.54) SIGMAR1L3MBTL1PRMT1MAPK1CYP19A1
SCHEMBL1361813 0.87 ALDH1A1 (0.64) PRMT1MAPK1
SCHEMBL4617661 0.84 SFRP1 (0.61) SIGMAR1L3MBTL1PARP1TP53MAPK1
SCHEMBL4769081 0.83 SIGMAR1 (0.74) SIGMAR1L3MBTL1PARP1TP53MAPK1
SCHEMBL4196782 0.83 SIGMAR1 (0.73) SIGMAR1L3MBTL1PARP1KDM4ELMNA
SCHEMBL2498510 0.82 L3MBTL1 (0.81) SIGMAR1L3MBTL1PARP1TP53MAPK1
SCHEMBL2854994 0.82 GAA (0.57) SIGMAR1L3MBTL1PARP1TP53MAPK1
SCHEMBL5438202 0.81 SIGMAR1 (0.73) SIGMAR1L3MBTL1PRMT1TP53MAPK1
Hydrochloric Acid SCHEMBL7966303 0.81 L3MBTL1 (0.79) SIGMAR1L3MBTL1PARP1TP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP disclosed
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES ICAGEN, INC. (US) 2008-03-13 US disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 US disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064690-A1 PYRAZOLE-AMIDES AND -SULFONAMIDES SCN3A, TRPV3, HCN3 SIGMAR1 694/4885L3MBTL1 4714/4885PRMT1 2611/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 SIGMAR1 694/4885L3MBTL1 4714/4885PRMT1 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.